FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360614918> ?p ?o ?g. }

• W4360614918 abstract "<h3>Background and Importance</h3> Various clinical trials, especially in oncology and haematology, involve chemiotherapic drugs compounding. These preparations require standard working procedures for which hospital pharmacist is responsible. Oncological drugs used in clinical trials are characterised by: low therapeutic index; unknown toxicity; dosage to be personalised on patient; assignment of number kit/placebo to specific patient; associations with other drugs not known in consolidated clinical practice. All these elements can contribute to the occurrence of potential errors. <h3>Aim and Objectives</h3> The aim of this study is to used Hazard Vulnerability Analysis in order to classify, into high, medium, low risk, experimental protocols that provide for chemiotherapic drugs compounding and which are currently active our hospital. For protocols classified as high risk, standard procedures will be outlined to minimise risks. <h3>Material and Methods</h3> In order to determine the percentage risk(R%), is calculated: probability(P) that an error will occur, by calculating the number of preparation-phases; magnitude(MA) by calculating carcinogenicity, storage time of preparation and chemical incompatibility between drugs and medical devices; mitigation(MI) by calculating drug dosage, chemical-physical preparation stability, possible use of safety-devices. By applying the formula R%=(P/3)*[(MA+MI)/18]*100, protocols are defined low-risk if R%<30%, moderate-risk if 30%≤R%≤60%, High-risk if R%>60%. <h3>Results</h3> Among 35 active clinical-trials analysed, 18 require chemiotherapic drugs compounding. For 33%(6/18) of protocols the probability is low; 50%(9/18) is moderate; 17%(3/18) is high. For 44%(8/18) of protocols the magnitude is low; 50%(9/18) is moderate; 6%(1/18) is high. Finally, for 6%(1/18) of protocols the mitigation is low; 88%(16/18) is moderate; 6%(1/18) is high. By applying the formula to calculate percentage risk it was found that 5/18 protocols are low risk, 10/18 moderate risk, 3/18 high risk. <h3>Conclusion and Relevance</h3> HVA provides a systematic approach to analysing hazards that may affect hospital service. Clinical protocols classified as ‘high risk’ have been monitored, and standard procedures have been outlined to minimise the risks (e.g. procedures for managing vial accidental breaking, cold chain control for prepared drugs, use of software to calculate drug dosage based on body surface). These procedures are aimed at all personnel involved in preparation phase, including the hospital pharmacist. Hospital pharmacist is coordinates whole process, deals with risk management and ensures personnel/patients safety. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest." @default.
• W4360614918 created "2023-03-24" @default.
• W4360614918 creator A5025442247 @default.
• W4360614918 creator A5033984961 @default.
• W4360614918 creator A5037136771 @default.
• W4360614918 creator A5046218691 @default.
• W4360614918 creator A5059339826 @default.
• W4360614918 creator A5068356708 @default.
• W4360614918 date "2023-03-01" @default.
• W4360614918 modified "2023-10-18" @default.
• W4360614918 title "5PSQ-024 Hazard vulnerability analysis (HVA): evaluation of risk in experimental oncological drugs compounding" @default.
• W4360614918 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.248" @default.
• W4360614918 hasPublicationYear "2023" @default.
• W4360614918 type Work @default.
• W4360614918 citedByCount "0" @default.
• W4360614918 crossrefType "proceedings-article" @default.
• W4360614918 hasAuthorship W4360614918A5025442247 @default.
• W4360614918 hasAuthorship W4360614918A5033984961 @default.
• W4360614918 hasAuthorship W4360614918A5037136771 @default.
• W4360614918 hasAuthorship W4360614918A5046218691 @default.
• W4360614918 hasAuthorship W4360614918A5059339826 @default.
• W4360614918 hasAuthorship W4360614918A5068356708 @default.
• W4360614918 hasBestOaLocation W43606149181 @default.
• W4360614918 hasConcept C112930515 @default.
• W4360614918 hasConcept C12174686 @default.
• W4360614918 hasConcept C126322002 @default.
• W4360614918 hasConcept C142724271 @default.
• W4360614918 hasConcept C177713679 @default.
• W4360614918 hasConcept C194828623 @default.
• W4360614918 hasConcept C204787440 @default.
• W4360614918 hasConcept C207673951 @default.
• W4360614918 hasConcept C2780035454 @default.
• W4360614918 hasConcept C2780385302 @default.
• W4360614918 hasConcept C38652104 @default.
• W4360614918 hasConcept C41008148 @default.
• W4360614918 hasConcept C535046627 @default.
• W4360614918 hasConcept C71924100 @default.
• W4360614918 hasConcept C98274493 @default.
• W4360614918 hasConceptScore W4360614918C112930515 @default.
• W4360614918 hasConceptScore W4360614918C12174686 @default.
• W4360614918 hasConceptScore W4360614918C126322002 @default.
• W4360614918 hasConceptScore W4360614918C142724271 @default.
• W4360614918 hasConceptScore W4360614918C177713679 @default.
• W4360614918 hasConceptScore W4360614918C194828623 @default.
• W4360614918 hasConceptScore W4360614918C204787440 @default.
• W4360614918 hasConceptScore W4360614918C207673951 @default.
• W4360614918 hasConceptScore W4360614918C2780035454 @default.
• W4360614918 hasConceptScore W4360614918C2780385302 @default.
• W4360614918 hasConceptScore W4360614918C38652104 @default.
• W4360614918 hasConceptScore W4360614918C41008148 @default.
• W4360614918 hasConceptScore W4360614918C535046627 @default.
• W4360614918 hasConceptScore W4360614918C71924100 @default.
• W4360614918 hasConceptScore W4360614918C98274493 @default.
• W4360614918 hasLocation W43606149181 @default.
• W4360614918 hasOpenAccess W4360614918 @default.
• W4360614918 hasPrimaryLocation W43606149181 @default.
• W4360614918 hasRelatedWork W185601289 @default.
• W4360614918 hasRelatedWork W2015075214 @default.
• W4360614918 hasRelatedWork W2265059493 @default.
• W4360614918 hasRelatedWork W2324605926 @default.
• W4360614918 hasRelatedWork W2426261983 @default.
• W4360614918 hasRelatedWork W2767696406 @default.
• W4360614918 hasRelatedWork W3184174631 @default.
• W4360614918 hasRelatedWork W4213271907 @default.
• W4360614918 hasRelatedWork W4252371801 @default.
• W4360614918 hasRelatedWork W10639847 @default.
• W4360614918 isParatext "false" @default.
• W4360614918 isRetracted "false" @default.
• W4360614918 workType "article" @default.